They now have a $34.39 price target on the biopharmaceutical company’s stock.
Advertisement
For the current quarter the company has high EPS estimates of $0.58 in contradiction of low EPS estimates of $0.52.
Last Trade: The Company rose 0.21% and finished at $32.78. 71,533,580 shares of the stock were exchanged. These are short term projections for the 12 months. The stock’s 50 day moving average price is $31.60 and its 200 day moving average price is $31.68. The company has a market cap of $201.74 billion.
Earnings were $3.0 billion, up 26.9 percent from the year-ago period. For 2016, Pfizer now expects earnings to be in a range of $2.38 to $2.48 per share – up from $2.20 to $2.30 per share, and revenue to lie between $51 billion and $53 billion – up from $49 billion to $51 billion range it projected in February.
Halliburton posted earnings of 7 cents per share on $4.2 billion in revenue, against the consensus estimates of 4 cents per share and $4.17 billion. Revenue for the period is expected to total almost $51.20B versus 48.85B in the preceding year. Similarly, its earnings grew 29 percent to $0.49 a share from $0.38 a share in the corresponding period of the past year. Analysts polled by Thomson Reuters had forecast $2.30 a share in earnings. The second-quarter 2016 cash dividend will be the 310th consecutive quarterly dividend paid by Pfizer. “The issue is does it make sense for our shareholders”. Forte Capital LLC ADV increased its position in Pfizer by 0.4% in the first quarter. These holdings make up 74.94% of the company’s outstanding shares. (NYSE:PFE) has been given an average broker rating of 1.77 on company shares. Brick & Kyle Associates increased its position in Pfizer by 1.9% in the fourth quarter.
Some analysts and investors have been pushing Pfizer for years to separate that business to accelerate growth, which the company until now has been trying to achieve with acquisitions and through more partnerships to develop new medicines.
Tying it togetherIt’s been years since Pfizer could be considered by investors to be a growth stock, but now that the negative impact of losing patent protection on its megablockbuster drug Lipitor in 2011 is behind it, Pfizer seems to be back on track.
Jefferies now has a Buy rating on Pfizer and a $39 price target. (NYSE:PFE) is “Outperform/Hold/Underperform/Buy while now 7 of the analysts have given “Buy” rating to the stock”. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.
Advertisement
But he said Pfizer is at least temporarily abandoning its quest to lower taxes by relocating overseas, a main rationale for buying Dublin-based Allergan.
